

Review of Treatment Options in Patients with Clinically Localized Prostate Cancer

*This measure is to be reported for all male patients, regardless of age, with clinically localized prostate cancer receiving interstitial prostate brachytherapy, external beam radiotherapy to the prostate, radical prostatectomy, or cryotherapy — a minimum of **once** per reporting period*

Measure description

Percentage of patients, regardless of age, with clinically localized prostate cancer AND receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who received counseling prior to initiation of treatment on, at a minimum, the following treatment options for clinically localized disease: active surveillance, AND interstitial prostate brachytherapy, AND external beam radiotherapy, AND radical prostatectomy

What will you need to report for each male patient with clinically localized prostate cancer receiving interstitial prostate brachytherapy, external beam radiotherapy to the prostate, radical prostatectomy, or cryotherapy for this measure?

If you select this measure for reporting, you will report:

- Whether or not you counseled the patient prior to initiation of treatment on, at a minimum, the following treatment options for clinically localized disease: active surveillance, AND interstitial prostate brachytherapy, AND external beam radiotherapy, AND radical prostatectomy

What if this process or outcome of care is not appropriate for your patient?

There may be times when it is not appropriate to counsel the patient on these treatment options, due to:

- Medical reasons (ie, salvage therapy)

In these cases, you will need to indicate that the medical reason applies, and specify the reason on the worksheet and in the medical chart. The office/billing staff will then report a code with a modifier that represents these valid reasons (also called exclusions).